Technical Analysis for IDRA - Idera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.15 9.69% 0.19
IDRA closed up 9.69 percent on Friday, January 17, 2020, on 2.96 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical IDRA trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Above Upper BB Strength 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish 9.69%
MACD Bullish Centerline Cross Bullish 9.69%
180 Bullish Setup Bullish Swing Setup 9.69%
Pocket Pivot Bullish Swing Setup 9.69%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on developing products for the treatment of autoimmune and inflammatory diseases. Its autoimmune and inflammatory disease programs include IMO-3100, an antagonist of TLR7 and TLR9, which has completed Phase II clinical trials for the treatment of psoriasis; and IMO-8400, an antagonist of TLR7, TLR8, and TLR9 that is in Phase I clinical trials for the treatment of psoriasis/lupus. The company's cancer program comprises IMO-2055, which has completed Phase Ib clinical trials for treatment of non-small cell lung cancer; and has completed Phase II clinical trials for the treatment of squamous cell, head and neck, and colorectal cancer. It is also developing IMO-2134 that has completed Phase I clinical trials to treat asthma and allergy. In addition, the company's research candidates include IMO-4200 for hematologic malignancies; and TLR3 Agonists for infectious diseases and other applications, as well as gene silencing oligonucleotides for inhibition of gene expression by targeting RNA. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to research, develop, and commercialize vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.
Biotechnology Health Cancer Biology Infectious Diseases Treatment Of Cancer Clinical Trial Alzheimer's Disease Non Small Cell Lung Cancer Genetics Psoriasis Gene Expression Asthma Allergy Colorectal Cancer Autoimmune And Inflammatory Diseases Hematologic Malignancies RNA Treatment Of Non Small Cell Lung Cancer Treatment Of Autoimmune And Inflammatory Diseases United Nations Treatment Of Psoriasis Gene Silencing Tlr7 Tlr9 Vaccine Products

Is IDRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.19
52 Week Low 1.45
Average Volume 239,890
200-Day Moving Average 2.48
50-Day Moving Average 1.88
20-Day Moving Average 1.83
10-Day Moving Average 1.87
Average True Range 0.14
ADX 20.0
+DI 38.70
-DI 12.63
Chandelier Exit (Long, 3 ATRs ) 1.81
Chandelier Exit (Short, 3 ATRs ) 1.88
Upper Bollinger Band 2.09
Lower Bollinger Band 1.57
Percent B (%b) 1.11
BandWidth 28.78
MACD Line 0.03
MACD Signal Line -0.01
MACD Histogram 0.0414
Fundamentals Value
Market Cap 321.7 Million
Num Shares 150 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -6.32
Price-to-Sales 13.60
Price-to-Book 2.94
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.53
Resistance 3 (R3) 2.51 2.38 2.46
Resistance 2 (R2) 2.38 2.28 2.38 2.44
Resistance 1 (R1) 2.26 2.22 2.32 2.28 2.42
Pivot Point 2.13 2.13 2.16 2.13 2.13
Support 1 (S1) 2.01 2.03 2.07 2.03 1.88
Support 2 (S2) 1.88 1.97 1.88 1.86
Support 3 (S3) 1.76 1.88 1.84
Support 4 (S4) 1.78